…
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in…
The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is…
Myriad Genetics (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.…
Investors are optimistic about Myriad Genetics (MYGN) strong solvency position and improvement in testing volume.…
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Myriad Genetics (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to…
Salt Lake City, Utah, March 13, 2024 (GLOBE NEWSWIRE) -- BioHive, a nonprofit public-private partnership dedicated to enhancing…
Myriad Genetics (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential…
Myriad Genetics target raised to $28 on firm outlook…
Earnings call: Myriad Genetics reports positive 2023 results, eyes growth…
…
Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.…
…
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad’s…
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched…
Dublin, Jan. 19, 2024 (GLOBE NEWSWIRE) -- The "Prenatal DNA Sequencing Global Market Report 2024" report has been…
…
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.…
…
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.…
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx…
Companies covered in this report are Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Myriad Genetics, Perkin…
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.…
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new…
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
…
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad…
…
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday…
…
Myriad Genetics (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.…
The Global Hereditary Testing Market Size was valued at USD 6.20 Billion in 2022 and the Worldwide Hereditary Testing Market…